Pharmacophore model for antiepileptic drugs acting on sodium channels
Fifteen antiepileptic drugs (AED), active against the maximal electroshock seizure test and able to block the neuronal voltage-dependent sodium channel, have been studied by means of a similarity analysis. Structural and electronic, quantum chemically derived characteristics are compared. Rigid anal...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2001
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 08249caa a22011897a 4500 | ||
|---|---|---|---|
| 001 | PAPER-1848 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203110.0 | ||
| 008 | 190411s2001 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0035789704 | |
| 024 | 7 | |2 cas |a carbamazepine, 298-46-4, 8047-84-5; dezinamide, 91077-32-6; ethosuximide, 77-67-8; felbamate, 25451-15-4; gabapentin, 60142-96-3; lamotrigine, 84057-84-1; oxcarbazepine, 28721-07-5; phenytoin, 57-41-0, 630-93-3; ralitoline, 93738-40-0; remacemide, 111686-79-4; rufinamide, 106308-44-5; topiramate, 97240-79-4; valproic acid, 1069-66-5, 99-66-1; vinpocetine, 42971-09-5; zonisamide, 68291-97-4 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a JMMOF | ||
| 100 | 1 | |a Tasso, S.M. | |
| 245 | 1 | 0 | |a Pharmacophore model for antiepileptic drugs acting on sodium channels |
| 260 | |c 2001 | ||
| 270 | 1 | 0 | |m Estiú, G.L.; CEQUINOR, Depto. de Ciencias Quimica, Universidad Nacional de La Plata, CC 962, 1900 La Plata, Argentina; email: estiu@biol.unlp.edu.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Bazil, C.W., Pedley, T.A., (1998) Annu. Rev. Med., 49, p. 135 | ||
| 504 | |a Balbes, L.M., Mascarella, S.W., Boyd, D.B., (1994) Reviews in Computational Chemistry, p. 337. , Lipkowitz KB, Boyd DB (eds) VCH, New York | ||
| 504 | |a Leach, J.P., (1997) CNS Drugs, 8 (5), p. 366 | ||
| 504 | |a Taylor, C.P., (1999) Jasper's Basic Mechanisms of the Epilepsies, pp. 1011-1026. , Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ (eds) 3rd edn: advances in neurology. Lippincott Williams & Wilkins, Philadelphia, Pa | ||
| 504 | |a Unverferth, K., Engel, J., Hofgem, N., Rostock, A., Gunther, R., Lankau, H., Menzer, M., Hofmann, H., (1998) J. Med. Chem., 41, p. 63 | ||
| 504 | |a Ragsdale, D.S., Avoli, M., (1998) Brain Res. Rev., 26, p. 16 | ||
| 504 | |a Delorenzo, R.J., (1995) Antiepileptic Drugs, p. 271. , Levy R, Mattson R, Meldrum B (eds) 4th edn. Raven Press, New York | ||
| 504 | |a Meldrum, B.S., (1996) Epilepsia, 37 (6), p. 4 | ||
| 504 | |a Loscher, W., Schmidt, D., (1994) Epilepsy Res., 17, p. 95 | ||
| 504 | |a Rogawski, M.A., Porter, R., (1990) J. Pharm. Rev., 42 (3), p. 223 | ||
| 504 | |a MacDonald, R.L., (1995) Antiepileptic Drugs, p. 491. , Levy R, Mattson R, Meldrum B (eds) 4th edn. Raven Press, New York | ||
| 504 | |a Shank, R.P., Gardocki, J.F., Vaught, J.L., (1994) Epilepsia, 35, p. 450 | ||
| 504 | |a Wilder, B.J., (1995) Neurology, 45 (2), p. 7 | ||
| 504 | |a Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P., Perucca, E., (1996) Epilepsy Res., 25, p. 299 | ||
| 504 | |a Leach, M.J., Lees, G., Riddall, D.R., (1995) Antiepileptic Drugs, p. 861. , Levy R, Mattson R, Meldrum B (eds) 4th edn. Raven Press, New York | ||
| 504 | |a Maryanoff, B.E., Costanzo, M.J., Nortey, S.O., Greco, M.N., Shank, R.P., Schupsky, J.J., Ortegon, M.P., Vaught, J.L., (1998) J. Med. Chem., 41, p. 1315 | ||
| 504 | |a Gladding, G.D., Kupferberg, H.J., Swinyard, E.A., (1985) Handbook of Experimental Pharmacology, pp. 341-347. , Frey H, Janz D (eds) Springer, Berlin | ||
| 504 | |a Porter, R.J., Cereghino, J.J., Gladding, G.D., Hessie, B.J., Kupferberg, H.J., Scoville, B., White, B.G., (1984) Clev. Clin. Q, 51, p. 293 | ||
| 504 | |a Tasso, S.M., Bruno-Blanch, L., Esti, G.L., (1997) Int. J. Quant. Chem., 65, p. 1107 | ||
| 504 | |a Brown, M.L., Zha, C.C., Van Dyke, C.C., Brown, G.B., Brouillette, W.J., (1999) J. Med. Chem., 42, p. 1537 | ||
| 504 | |a Tasso, S., Bruno-Blanch, L., Moon, S., Esti, G., (2000) J. Mol. Struct. (Theochem), 504, p. 229 | ||
| 504 | |a Molnar, P., Erdo, S.L., (1995) Eur. J. Pharmacol., 273, p. 303 | ||
| 504 | |a Fariello, R.G., Varasi, M., Smith, M.C., (1995) Antiepileptic Drugs, p. 581. , Levy R, Mattson R, Meldrum B (eds) 4th edn. Raven Press, New York | ||
| 504 | |a Taylor, C.P., (1995) Antiepileptic Drugs, p. 829. , Levy R, Mattson R, Meldrum B (eds) 4th edn. Raven Press, New York | ||
| 504 | |a Dam, M., Ostergaard, L.H., (1995) Antiepileptic Drugs, p. 987. , Levy R, Mattson R, Meldrum B (eds) 4th edn. Raven Press, New York | ||
| 504 | |a Gram, L., (1989) Antiepileptic Drugs, pp. 947-953. , Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE (eds) 3rd edn. Raven Press, New York | ||
| 504 | |a Willow, M., Catterall, W.A., (1982) Mol. Pharmacol., 22, p. 627 | ||
| 504 | |a Willow, M., Kuenzel, E.A., Catterall, W.A., (1984) Mol. Pharmacol., 25, p. 228 | ||
| 504 | |a Chen, A., Weston, J.K., Bratton, A.C., (1963) Epilepsia, 4, p. 66 | ||
| 504 | |a Ferrendelli, J.A., Holland, K.D., (1989) Antiepileptic Drugs, pp. 653-661. , Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE (eds) 3rd edn. Raven Press, New York | ||
| 504 | |a Stewart, J.J.P., Seiler, F.J., Mopac, version 7.0 (1994), Research Laboratory, United States Air Force Academy, Co; (1997), Spartan Wavefunction, Irvine, Calif; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Zakrzewski, V.G., Pople, J.A., Pa (1998) Gaussian 98, , Gaussian, Pittsburgh | ||
| 520 | 3 | |a Fifteen antiepileptic drugs (AED), active against the maximal electroshock seizure test and able to block the neuronal voltage-dependent sodium channel, have been studied by means of a similarity analysis. Structural and electronic, quantum chemically derived characteristics are compared. Rigid analogs are included, because of the flexibility of some structures, in order to discern the conformational requirements associated with these ligands in the moment of the interaction. An inactive compound (ethosuximide) helps in the definition of the structural factors that are important for the activity. We propose a pharmacophore model that, giving an interpretation of the biological activity, allows the design of new AED with a well-defined mechanism of interaction. |l eng | |
| 593 | |a Química Medicinal, Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, CC 243, 1900 La Plata, Argentina | ||
| 593 | |a CEQUINOR, Depto. de Ciencias Quimica, Universidad Nacional de La Plata, CC 962, 1900 La Plata, Argentina | ||
| 593 | |a DQIAyFQ, Fac. de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pb 2, Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a ANTIEPILEPTIC |
| 690 | 1 | 0 | |a PHARMACOPHORE |
| 690 | 1 | 0 | |a QUANTUM CHEMICAL MOLECULAR DESIGN |
| 690 | 1 | 0 | |a RATIONAL DRUG DESIGN |
| 690 | 1 | 0 | |a SODIUM CHANNEL |
| 690 | 1 | 0 | |a ANTICONVULSIVE AGENT |
| 690 | 1 | 0 | |a CARBAMAZEPINE |
| 690 | 1 | 0 | |a DEZINAMIDE |
| 690 | 1 | 0 | |a ETHOSUXIMIDE |
| 690 | 1 | 0 | |a FELBAMATE |
| 690 | 1 | 0 | |a GABAPENTIN |
| 690 | 1 | 0 | |a LAMOTRIGINE |
| 690 | 1 | 0 | |a OXCARBAZEPINE |
| 690 | 1 | 0 | |a PHENYTOIN |
| 690 | 1 | 0 | |a RALITOLINE |
| 690 | 1 | 0 | |a REMACEMIDE |
| 690 | 1 | 0 | |a RUFINAMIDE |
| 690 | 1 | 0 | |a SODIUM CHANNEL |
| 690 | 1 | 0 | |a SODIUM CHANNEL BLOCKING AGENT |
| 690 | 1 | 0 | |a TOPIRAMATE |
| 690 | 1 | 0 | |a VALPROIC ACID |
| 690 | 1 | 0 | |a VINPOCETINE |
| 690 | 1 | 0 | |a ZONISAMIDE |
| 690 | 1 | 0 | |a ANTICONVULSANT ACTIVITY |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CHEMICAL INTERACTION |
| 690 | 1 | 0 | |a COMPUTER MODEL |
| 690 | 1 | 0 | |a CONFORMATION |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DRUG MECHANISM |
| 690 | 1 | 0 | |a DRUG POTENCY |
| 690 | 1 | 0 | |a DRUG STRUCTURE |
| 690 | 1 | 0 | |a ELECTRIC SHOCK |
| 690 | 1 | 0 | |a NERVE BLOCK |
| 690 | 1 | 0 | |a PHARMACOPHORE |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a QUANTITATIVE STRUCTURE ACTIVITY RELATION |
| 690 | 1 | 0 | |a QUANTUM CHEMISTRY |
| 690 | 1 | 0 | |a SEIZURE |
| 700 | 1 | |a Bruno-Blanch, L.E. | |
| 700 | 1 | |a Estiú, G.L. | |
| 773 | 0 | |d 2001 |g v. 7 |h pp. 231-239 |k n. 7 |p J. Mol. Model. |x 16102940 |t Journal of Molecular Modeling | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035789704&doi=10.1007%2fS008940100033&partnerID=40&md5=576300bce9b26f61ee12b85dc6517834 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1007/S008940100033 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_16102940_v7_n7_p231_Tasso |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_16102940_v7_n7_p231_Tasso |y Registro en la Biblioteca Digital |
| 961 | |a paper_16102940_v7_n7_p231_Tasso |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 62801 | ||